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BACKGROUND: COIN compared first-line continuous chemotherapy with the same chemotherapy given intermittently or with
cetuximab in advanced colorectal cancer (aCRC).
METHODS: Choice between oxaliplatin/capecitabine (OxCap) and oxaliplatin/leucovorin (LV)/infusional 5-FU (OxFU) was by physician
and patient choice and switching regimen was allowed. We compared OxCap with OxFU and OxCapþ cetuximab with
OxFUþ cetuximab retrospectively in patients and examined efficacy, toxicity profiles and the effect of mild renal impairment.
RESULTS: In total, 64% of 2397 patients received OxCap(±cetuximab). Overall survival, progression free survival and overall response
rate were similar between OxCap and OxFU but rate of radical surgeries was higher for OxFU. Progression free survival was longer
for OxFUþ cetuximab compared with OxCapþ cetuximab but other efficacy measures were similar. Oxaliplatin/LV/infusional 5-FU
(±cetuximab) was associated with more mucositis and infection whereas OxCap(±cetuximab) caused more gastrointestinal
toxicities and palmar-plantar erythema. In total, 118 patients switched regimen, mainly due to toxicity; only 16% came off their
second regimen due to intolerance. Patients with creatinine clearance (CrCl) 50–80mlmin 1 on OxCap(±cetuximab) or
OxFUþ cetuximab had more dose modifications than those with better renal function.
CONCLUSIONS: Overall, OxFU and OxCap are equally effective in treating aCRC. However, the toxicity profiles differ and switching
from one regimen to the other for poor tolerance is a reasonable option. Patients with CrCl 50–80mlmin 1 on both regimens
require close toxicity monitoring.
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Intravenous (IV) 5-FU has been the backbone of treatment for
advanced colorectal cancer (aCRC) for over 40 years. Currently
capecitabine, an oral fluoropyrimidine (Fp) prodrug, is commonly
used as a convenient and effective alternative.
Two large phase III randomised trials compared capecitabine
1250 mg m 2 twice daily for 14 days repeated every 3 weeks to the
Mayo Clinic regimen (Mayo) of IV leucovorin (LV) 20 mg m 2
followed by daily bolus 5-FU 425 mg m 2 for 5 days repeated every 4
weeks. Integrated data analysis of the two trials has shown similar
overall survival (OS) and progression free survival (PFS) between the
two regimens (Van Cutsem et al, 2004). In comparison with Mayo,
capecitabine appeared to have a better toxicity profile and to be a
safer treatment option for patients with moderate renal impairment.
It was also shown that the standard starting dose of capecitabine was
safe for patients with mild renal impairment; however, it was
recommended that such patients should be monitored closely with
prompt treatment interruption and dose reduction in the event of a
grade 2 or higher toxicity (Cassidy et al, 2002).
Bolus 5-FU has largely been replaced with a continuous infusion
in current treatment regimens. The de Gramont (LV5FU2) regimen
of LV/infusional 5FU was compared with Mayo in a randomised
trial. LV5FU2 was not only less toxic but was also associated with a
better response rate (RR) and PFS (de Gramont et al, 1997).
Oxaliplatin is used in combination with either 5-FU (OxFU) or
capecitabine (OxCap). Several phase III studies have compared
OxFU with OxCap as first-line treatment for aCRC including: the
German AIO (Porschen et al, 2007), the Spanish TTD (Diaz-Rubio
et al, 2007), the international NO16966 (Cassidy et al, 2008) and
the French FNCLCC (Ducreux et al, 2011). All four of these trials,
together with two smaller ones, were included in a meta-analysis
that showed similar PFS and OS but an inferior overall RR (ORR)
for OxCap. Thrombocytopenia, diarrhoea and palmar-plantar
erythema (PPE) were more prominent with OxCap-based regimens
whereas neutropenia was more prominent with OxFU (Arkenau
et al, 2008).
COIN is a three-arm multi-centre phase III open-label
randomised controlled trial of the MRC, London. It compared
standard continuous chemotherapy with OxFU or OxCap (Arm A)
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to each of two experimental arms: same chemotherapy plus
cetuximab (Arm B) or intermittent chemotherapy without
cetuximab (Arm C). The choice between OxFU and OxCap was
nonrandomised but was agreed between the patient and treating
clinician before randomisation. COIN did not meet either of its
primary outcome measures as the addition of cetuximab was not
associated with an improvement in efficacy (Maughan et al, 2011),
and intermittent chemotherapy was not confirmed to be non-
inferior to continuous treatment (Adams et al, 2011).
We report a retrospective analysis comparing OxCap with OxFU
and OxCapþ cetuximab with OxFUþ cetuximab in terms
of efficacy and severe side effects. We also examine the success
of switching from one OxFp regimen to the alternate as a strategy
for keeping patients on first-line treatment in case of intolerance to
the first regimen chosen. Following the recommendation from
Cassidy et al (2002) to monitor patients with mild renal
impairment, we investigate the effect of renal impairment on
toxicity on both OxFp regimens. None of these analyses were pre-
specified in the COIN trial protocol.
MATERIALS AND METHODS
Patients
Accrual took place in 110 centres in the United Kingdom and
the Republic of Ireland between March 2005 and May 2008.
Patients (ageX18) had: measurable metastatic or locally advanced
colorectal adenocarcinoma; no previous chemotherapy for
advanced disease; WHO performance status (PS) 0–2; adequate
bone marrow, liver and kidney function. Patients were excluded
if they had: CrClo50 ml min 1; brain metastases; prior adjuvant
treatment with oxaliplatin; uncontrolled medical co-morbidity; or
were being considered for liver metastasectomy after initial down-
staging chemotherapy.
Treatment plan
OxCap was given as per the XELOX regimen (3-weekly cycles of
IV oxaliplatin 130 mg m 2 over 2 h on day 1 followed by
capecitabine 1000 mg m 2 b.i.d. for 2 weeks). An analysis of the
toxicity profile of the regimens after 800 patients had been
randomised to the trial showed that the rate of severe diarrhoea for
OxCapþ cetuximab was excessive at 30% (Adams et al, 2009).
Therefore, a protocol amendment in July 2007 mandated that the
capecitabine dose in Arm B be reduced from 1000 to 850 mg m 2
b.i.d. for all future trial patients. Those already on trial had the
choice to remain on the higher dose if well tolerated.
OxFU was a 2-weekly regimen of IV L-LV 175 or D,L-LV 350 mg
given concurrently with oxaliplatin 85 mg m 2 over 2 h on day 1,
followed by IV bolus 5-FU 400 mg m 2 and finally 5-FU
2400 mg m 2 infused over 46 h. This regimen requires an
indwelling venous line (IVL) and is referred to as OxMdG in the
United Kingdom.
Switching from one regimen to another was allowed for toxicity,
compliance, logistics or patient’s choice. All patients switching
from OxFU to OxCap had their dose of capecitabine reduced
to 850 mg m 2 in the first cycle as the retained intracellular LV can
potentially increase capecitabine toxicity (Hennig et al, 2008).
In Arm B, cetuximab was given in a loading dose of 400 mg m 2
IV over 2 h on day 1 and subsequently at 250 mg m 2 over 1 h once
a week.
Response was assessed every 12 weeks using the RECIST 1.0
criteria. In both Arms A and B, treatment was continued until
disease progression, unacceptable toxicities or patient’s choice. In
Arm C, treatment was stopped after 12 weeks and patients with
responding or stable disease had a break from chemotherapy but
this was restarted on evidence of clinical or radiological disease
progression. An unlimited number of 12 week courses were
allowed until evidence of treatment failure, which is defined as
disease progression on or shortly after stopping treatment.
Renal function
Patients were required to have a baseline CrCl X50 ml min 1 as
estimated using the Cockcroft and Gault formula (Cockcroft and
Gault, 1976). For the purpose of this analysis patients were divided
into two CrCl groups: 480 and 50–80 ml min 1 corresponding to
normal renal function and mild renal impairment, respectively.
This is in line with the study by Cassidy et al (2002) in which the
lower cut points for mild renal impairment and normal renal
function were set at 51 and 81 ml min 1, respectively.
Efficacy outcome measures
The following outcome measures were compared: OS, PFS and RR
at 12 weeks, ORR, and rate of radical surgeries (RRS). Overall RR is
defined as the proportion of patients who had PR or CR while on
treatment. Rate of radical surgeries is defined as the proportion of
patients who had surgery to remove metastatic and/or primary
disease with curative intent after starting trial treatment.
Toxicity
Toxicities were graded according to an increasing severity scale of
1–5 based on the NCI Common Terminology Criteria for Adverse
Events v3.0. We compared the following ‘grade 3 or worse’ (G3þ )
toxicities between the two regimens: nausea, vomiting, diarrhoea,
mucositis, lethargy, PPE, neuropathy, thrombocytopenia, neutro-
penia and treatment-related infection. The latter was defined as
infection with G3/4 neutropenia or any IVL-related infection. Also,
we compared rates of dose modification (reductions and delays) in
the first 12 weeks of treatment.
Statistics
Arms A and C were combined for all analyses except PFS given the
intermittent nature of treatment in Arm C. Comparisons were also
made separately in each of Arms A, B and C. However, when
looking at reasons for switching from one regimen to another,
patients across all arms were combined to maximise power.
Patients were classified according to the chemotherapy regimen
(OxCap or OxFU) used in their first cycle. Those who did not
receive any trial treatment were excluded from all analyses and
those who switched regimen were included in toxicity analyses for
toxicities of the first regimen, but were excluded from all efficacy
analyses.
OxCap was regarded as the control group for HR and OR
calculations. Pearson’s w2 tests were used to calculate P-values, and
for cells with low count (no5) Fisher’s exact test was used instead;
P-values o0.05 were considered significant. Survival curves were
plotted using the Kaplan–Meier method. Unadjusted and stratified
HR was estimated using the Peto log-rank method, and OR using
the Mantel–Haenszel method. For adjusted HR and OR, Cox and
logistic regressions were used, respectively.
Efficacy and toxicity outcome measures were corrected for
predefined prognostic factors (PFs), and whenever arms were
combined correction was also made for trial arm membership.
Prognostic factors (PFs)
Prognostic factors for efficacy outcome measures were determined
using a backward stepwise selection procedure, and was carried
out separately for OS, PFS and ORR. There was a considerable
overlap in PFs for each of these outcome measures. Therefore, the
final set of PFs included those that appeared for any of the three
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outcomes: sex, white blood cell count, alkaline phosphatase level,
the presence of tumour mutation in KRAS, BRAF or NRAS (all
wild-type vs any mutant gene), WHO PS (0/1 vs 2), number of
metastatic sites (0/1 vs 2) and synchronous vs metachronous
metastases. Data on tumour mutation status were missing for some
patients. To minimise the resulting loss of statistical power,
multiple imputation was used when fitting models entering
mutation status (Rubin, 1987). Where the outcome was time-to-
event, the Nelson–Aalen estimator and event indicator were
entered into the imputation model as suggested by White and
Royston (2009). Both adjusted and unadjusted comparisons for
efficacy outcome measures are presented hereafter.
PFs for toxicity were determined through the same procedure
using the outcome ‘any G3þ toxicity vs none’. These were as
follows: CrCl, age and WHO PS.
RESULTS
Patients
See consort diagram (Figure 1). A total of 2445 patients were
accrued between 2005 and 2008, of whom 2397 patients received at
least one cycle of treatment. In all, 64% of patients received OxCap
(±cetuximab) and 36% OxFU (±cetuximab). Tumour mutation
status was unknown for 20% of patients. Baseline characteristics
were largely balanced between the two regimens but patients
on OxFU in each of Arm A and Arm B had higher cumulative
dose of oxaliplatin compared with those on OxCap in each of the
respective arm (Table 1). In all, 29% of patients on OxCapþ
cetuximab started on the reduced dose of capecitabine as per
protocol amendment.
In total, 118 patients (5%) had a change in Fp regimen during
trial treatment, 59 in each group corresponding to 4% and 7% of
patients on OxCap (±cetuximab) and OxFU (±cetuximab),
respectively. Reasons for switching regimen were (% out of
patients who switched): IVL complications 0 (0%) and 42 (71%),
toxicity (not further specified by centres) 45 (76%) and 6 (10%),
and patient’s choice or compliance issues 13 (22%) and 10 (17%)
of patients on OxCap (±cetuximab) and OxFU (±cetuximab),
respectively; the reason was unknown for 1 patient in each group
(2%). w2 test for difference in distribution of reasons¼ 72.2 on 2
degrees of freedom; Po0.001.
Although all patients who switched from OxCap (±cetuximab)
remained on OxFU (±cetuximab) until they came off trial, 13
(22%) of those who switched from OxFU (±cetuximab) later
returned to their original regimen after receiving, on average, two
OxCap cycles. In most cases this was a temporary measure after the
IVL was removed, due to a complication, to avoid treatment delays
or the need for IVL re-insertion when patients in Arm C were
about to go on a treatment break.
There was no excess of intolerance to the second regimen in
patients who switched regimen once: 17 patients (16%) out of this
group came off trial due to toxicity or patient’s choice compared
with 436 (19%) of those who never switched (P¼ 0.45).
Efficacy
Survival Overall, 2279 patients were included in the efficacy
analyses after excluding those who switched regimen (Table 2 and
Figures 2 and 3). Overall survival was similar for OxCap and OxFU
with a median of 15.4 and 14.9 months, respectively; adjusted HR
0.92 (0.78, 1.09). Also, there was no difference in PFS: 7.4 and 8.8
months, respectively; adjusted HR 0.90 (0.77, 1.06).
OS was similar between OxCapþ cetuximab and OxFUþ
cetuximab but PFS was longer for OxFUþ cetuximab at 8.5
compared with 7.4 months for OxCapþ cetuximab: adjusted HR
OxCap: 1575 (64%)
Arm A: 525 (33%)
Arm B: 523 (33%)
Arm C: 527 (34%)
OxFU: 822 (36%)
Arm A: 266 (32%)
Arm B: 279 (34%)
Arm C: 277 (34%)
aCRC, CrCl ≥50 ml min–1
choice between OxCap and OxFU
Consented: 2445 patients
Commenced treatment: 2397
Remained on OxFU:
Arm A: 251 (33%)
Arm B: 259 (34%)
Arm C: 253 (33%)
Remained on OxCap:
Arm A: 506 (33%)
Arm B: 503 (33%)
Arm C: 507 (33%)
Efficacy analyses
Switched to OxCap: 59 (7%)
Switched back to OxFU:
13 (22%)
Switched to OxFU: 59 (4%)
Switched back to OxCap:
0 (0%)
Toxicity analyses
Of which CrCl:
50–80 ml min–1
 131 (30%) 132 (35%)
 154 (35%) 123 (33%)
 154 (35%) 122 (32%)
Of which CrCl:
50–80 ml min–1
 265 (33%) 257 (34%)
 268 (33%) 247 (33%)
 272 (34%) 252 (33%)
>80 ml min–1 >80 ml min–1
Figure 1 CONSORT diagram.
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0.79 (0.67, 0.93). Progression free survival analysis was repeated
using only patients who were randomised before capecitabine
dose reduction was mandated for Arm B but the pattern stayed the
same: adjusted HR 0.79 (0.65, 0.94), P¼ 0.010.
Response and radical surgery Response rate at 12 weeks and ORR
were similar in each of the two comparisons: OxCap vs OxFU and
OxCapþ cetuximab vs OxFUþ cetuximab.
Across all arms, 119 patients (5%) in the efficacy sample
underwent radical surgery, of which 74% were liver metastasec-
tomies, 13% lung metastasectomies, 9% primary resections (with
or without liver metastasectomy) and 4% other sites. Rate
of radical surgeries was higher for OxFU (6.5%) compared with
OxCap (3.5%): adjusted OR 1.96 (1.18, 3.23) whereas RRS was
similar between OxFUþ cetuximab and OxCapþ cetuximab.
Toxicity Rate of ‘any G3þ toxicity’ was higher for OxFU at 64%
compared with 57% for OxCap, P¼ 0.008 (Table 3). However, after
exclusion of asymptomatic neutropenia and thrombocytopenia
rates became similar at 55% and 56%, respectively (P¼ 0.84).
Mucositis, neutropenia, treatment-related infections and neuro-
pathy were significantly higher in the OxFU group with rates of
4%, 28%, 10% and 13% vs 1%, 3%, 1% and 10% for OxCap.
Conversely, rates for nausea, diarrhoea and PPE were higher for
OxCap at 8%, 16% and 4% vs 5%, 10% and 1% for OxFU. Dose
reductions were more common for capecitabine, whereas dose
delays were more common for OxFU. The differences in toxicity
rates between OxFUþ cetuximab and OxCapþ cetuximab
followed a similar pattern to those of OxFU vs OxCap. There was
no difference in rates of treatment-related mortality in any of the
analyses.
Table 1 Baseline characteristics: OxCap vs OxFU
Arm A Arm B (þ cetuximab) Arm C Total
Regimen OxCap OxFU OxCap OxFU OxCap OxFU OxCap OxFU
Total N patients 525 266 523 279 527 277 1575 822
Sex
Female 187 (36%) 95 (36%) 168 (32%) 97 (35%) 181 (34%) 105 (38%) 536 (34%) 297 (36%)
Age
65þ 239 (46%) 120 (45%) 241 (46%) 135 (48%) 255 (48%) 108 (39%) 735 (47%) 363 (44%)
Median age (IQR) 63 (56, 69) 63 (57, 69) 64 (58, 70) 64 (58, 70) 64 (58, 70) 62 (57, 69) 64 (57, 70) 63 (57, 69)
WHO PS
2þ 34 (6%) 22 (8%) 37 (7%) 23 (8%) 37 (7%) 22 (8%) 108 (7%) 67 (8%)
Current status of primary tumour
Resected 290 (55%) 145 (55%) 269 (51%) 145 (52%) 261 (50%) 153 (55%) 820 (52%) 443 (54%)
Type of metastases
Liver only 108 (21%) 62 (23%) 122 (23%) 69 (25%) 102 (19%) 76 (27%) 332 (21%) 207 (25%)
Liver 389 (74%) 205 (77%) 389 (74%) 215 (77%) 389 (74%) 214 (77%) 1167 (74%) 634 (77%)
Lung 206 (39%) 113 (43%) 218 (42%) 113 (40%) 219 (42%) 107 (38%) 643 (41%) 333 (41%)
Other (including
nodes and
peritoneum)
329 (63%) 149 (56%) 301 (58%) 164 (59%) 325 (62%) 151 (54%) 955 (61%) 464 (56%)
Mean number of
metastatic sites
1.93 1.94 1.88 1.94 1.95 1.86 1.92 1.92
Site of primary tumour
Colon 287 (55%) 153 (58%) 284 (54%) 152 (55%) 272 (52%) 160 (58%) 843 (53%) 465 (57%)
Rectum 162 (31%) 76 (28%) 167 (32%) 92 (33%) 168 (32%) 79 (28%) 497 (32%) 247 (30%)
Rectosigmoid
junction
75 (14%) 36 (13%) 72 (14%) 34 (12%) 86 (16%) 38 (14%) 233 (15%) 108 (13%)
Other and missing
data
1 (o1%) 1 (o1%) 0 (0%) 1 (o1%) 1 (o1%) 0 (0%) 2 (o1%) 2 (o1%)
CrCl groups
Normal
(480mlmin 1)
265 (50%) 131 (49%) 268 (51%) 154 (55%) 272 (52%) 154 (56%) 805 (51%) 439 (53%)
Impaired
(50–80mlmin 1)
257 (49%) 132 (50%) 247 (47%) 123 (44%) 252 (48%) 122 (44%) 756 (48%) 377 (46%)
Other
(o50 or missing)
3 (1%) 3 (1%) 8 (2%) 2 (1%) 3 (1%) 1 (o1%) 14 (1%) 6 (1%)
Second-line therapya
Eligible 477 (91%) 239 (90%) 452 (86%) 240 (86%) 436 (83%) 206 (74%) 1365 (87%) 685 (83%)
Chemotherapy 278 (58%) 159 (67%) 242 (54%) 135 (56%) 217 (50%) 113 (55%) 737 (54%) 407 (59%)
Biological 29 (6%) 18 (8%) 26 (6%) 21 (9%) 23 (5%) 15 (7%) 78 (6%) 54 (8%)
Total dose of oxaliplatin (mg)
Median (IQR) 797 (464, 1035) 848 (498, 1023) 682 (397, 1016) 806 (486, 1018) 528 (454, 1003) 520 (458, 966) 652 (436, 1024) 741 (481, 1016)
Abbreviations: CrCl¼ creatinine clearance; OxCap¼ oxaliplatin/capecitabine; OxFU¼ oxaliplatin/leucovorin (LV)/infusional 5-FU; PS¼ performance status. aPatients (within the
sample used throughout this analysis) were considered eligible for second-line therapy if they had come off trial and were not lost to follow-up. Loss to follow-up was defined as
no data being received within 6 months of data freeze. Rates of chemotherapy and biologicals received are with respect to numbers eligible.
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Toxicity and renal impairment In the OxCap group, patients with
CrCl 50–80 ml min 1 had higher rates of G3þ nausea (Table 4),
diarrhea and thrombocytopenia compared with patients of CrCl
480 ml min 1: 11%, 19% and 4% compared with 5%, 11% and
1%, respectively. There was also a higher rate of dose delays: 49%
compared with 38%, respectively.
In the OxFU group, there was no statistically significant
difference for any of the toxicities or in dose modification between
the two CrCl groups.
In the OxCapþ cetuximab group, patients with CrCl
50–80 ml min 1 had a higher rate of G3þ lethargy (29% vs
17%) and more reductions in the capecitabine dose (67% vs 53%)
compared with those of CrCl 480 ml min 1.
In the OxFUþ cetuximab group, G3þ neutropenia was higher
in patients with CrCl 50–80 ml min 1 compared with those of CrCl
480 ml min 1 (36% vs 23%) and so were the rates of dose delays
(76% vs 66%) and reductions for both oxaliplatin (39% vs 26%)
and 5-FU (56% vs 39%).
There was no difference in treatment-related deaths in any
of the comparisons.
DISCUSSION
This paper compared OxCap with OxFU given in the XELOX and
OxMdG regimens, respectively. The latter regimen is widely used
in the United Kingdom and is similar to FOLFOX6 (Braun et al,
2003). XELOX and FOLFOX6 were compared in the French study
reported by Ducreux et al (2011), which showed in a per protocol
analysis that XELOX is non-inferior to FOLFOX6 in terms of ORR
(primary outcome measure), PFS and OS. Our retrospective
analysis of the COIN data confirms that OxCap (XELOX) is
equivalent to OxFU (OxMdG) in terms of the three efficacy
measures, and is overall in line with the results of the meta-
analysis by Arkenau et al (2008). However, the meta-analysis
demonstrated an inferior ORR for OxCap (OR 0.85; 95%
CI 0.74–0.97). Both ORR and RRS in our study were numerically
Table 2 Efficacy outcome measures: OxCap vs OxFU
Regimen
OxCap OxFU Measure of association (unadjusted) Measure of association (adjusteda)
Outcome
measure Subgroup
Median survival
(months) HR (95% CI) P-value HR (95% CI) P-value
OS Arms A and C 15.4 14.9 1.02 (0.90, 1.15) 0.80 0.92 (0.78, 1.09) 0.33
Arm A 16.0 15.8 1.00 (0.84, 1.19) 0.99 0.95 (0.80, 1.14) 0.58
Arm B 15.0 14.9 1.01 (0.86, 1.20) 0.87 0.94 (0.79, 1.12) 0.51
Arm C 13.8 13.8 1.03 (0.87, 1.23) 0.72 1.05 (0.88, 1.25) 0.59
PFS Arm A 7.4 8.8 0.93 (0.79, 1.08) 0.34 0.90 (0.77, 1.06) 0.20
Arm B 7.4 8.5 0.82 (0.70, 0.96) 0.011 0.79 (0.67, 0.93) 0.004
% Rate OR (95% CI) P-value OR (95% CI) P-value
RR at 12 weeks Arms A and C 45% 47% 1.05 (0.85, 1.30) 0.65 1.06 (0.85, 1.32) 0.61
Arm B 47% 46% 0.95 (0.71, 1.29) 0.76 0.99 (0.72, 1.36) 0.95
ORR Arms A and C 51% 54% 1.16 (0.94, 1.44) 0.17 1.18 (0.94, 1.47) 0.15
Arm A 51% 55% 1.16 (0.86, 1.58) 0.33 1.18 (0.86, 1.62) 0.30
Arm B 51% 57% 1.26 (0.93, 1.70) 0.14 1.35 (0.98, 1.86) 0.069
Arm C 50% 54% 1.16 (0.86, 1.57) 0.34 1.16 (0.85, 1.59) 0.36
RRS Arms A and C 3.5% 6.5% 1.96 (1.21, 3.20) 0.006 1.96 (1.18, 3.23) 0.009
Arm A 4.2% 9.6% 2.44 (1.34, 4.45) 0.003 2.43 (1.30, 4.54) 0.005
Arm B 6.4% 7.3% 1.17 (0.65, 2.09) 0.61 1.27 (0.69, 2.33) 0.44
Arm C 2.8% 4.0% 1.45 (0.65, 3.25) 0.38 1.25 (0.53, 2.96) 0.61
Abbreviations: CI¼ confidence interval; HR¼ hazard ratio; ORR¼ overall response rate; OR¼ odds ratio; OS¼ overall survival; PS¼ performance status; RRS¼ rate of radical
surgeries; OxCap¼ oxaliplatin/capecitabine; OxFU¼ oxaliplatin/leucovorin (LV)/infusional 5-FU. aMultiple imputation was used for ‘any mutation’.
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higher for OxFU; this reached statistical significance for RRS but
not ORR despite the size of the study.
OxFUþ cetuximab and OxCapþ cetuximab were also equivalent
in terms of OS, ORR and RRS. Nonetheless, PFS was longer for
OxFUþ cetuximab and this remained the case after repeating the
analyses using only patients who were randomised before the
protocol mandated capecitabine dose reduction. This observation
is consistent with the positive interaction for cetuximab with the
Fp partner in favour of 5-FU, which was demonstrated by the
exploratory analyses of Arm B vs Arm A (Maughan et al, 2011). A
possible explanation would be the higher toxicity for OxCapþ
cetuximab, which led to more dose reductions and a lower total
dose of oxaliplatin: 682 mg for OxCapþ cetuximab vs 806 mg for
OxFUþ cetuximab. Our study also confirmed that OxCap and
OxFU have different toxicity profiles with OxFU being associated
with higher rates of G3þ mucositis, neutropenia and treatment-
related infections, and OxCap being associated with higher rates of
G3þ nausea, diarrhoea and PPE. Of note, more patients on OxFU
had G3þ neuropathy, which was limited to Arm A in the
individual arm analysis: 22% vs 16% for patients on OxFU and
OxCap, respectively. This may be explained by the 6% higher
cumulative dose of oxaliplatin for patients on OxFU compared
with OxCap in Arm A: 848 and 797 mg, respectively.
The rate of patients who came off their second regimen after
switching from OxFU (±cetuximab) to OxCap (±cetuximab) or
vice versa was only 16%. This success in switching from one
regimen to the other in keeping patients on first-line chemother-
apy can be explained by the differing acceptability to patients of
specific toxicity profiles.
Patients with CrCl 50–80 ml min 1 on OxCap had more G3þ
toxicities and dose delays compared with those of CrCl
480 ml min 1. This discrepancy was not observed between the
two CrCl groups in patients on OxFU. However, patients on
OxFUþ cetuximab with mild renal impairment required more
dose modifications compared with patients of CrCl480 ml min 1
on the same regimen.
In conclusion: (I) OxFU (OxMdG) and OxCap (XELOX) have
similar efficacy in the first-line treatment for aCRC. (II) OxFU is a
better chemotherapy partner for cetuximab than OxCap because of
less diarrhoea and longer PFS. (III) Toxicity patterns differ and
Table 3 G3þ toxicity: OxCap vs OxFU
Arms A and C Arm A Arm B (þ cetuximab) Arm C
OxCap OxFU OxCap OxFU OxCap OxFU OxCap OxFU
G3þ toxicity N (%) N (%) P-value N (%) N (%) P-value N (%) N (%) P-value N (%) N (%) P-value
Any toxicity 601 (57%) 349 (64%) 0.008 305 (58%) 187 (70%) 0.002 383 (73%) 225 (81%) 0.031 296 (56%) 162 (58%) 0.53
Nausea 87 (8%) 27 (5%) 0.013 36 (7%) 13 (5%) 0.17 46 (9%) 16 (6%) 0.11 51 (10%) 14 (5%) 0.032
Vomiting 61 (6%) 24 (4%) 0.23 27 (5%) 10 (4%) 0.32 36 (7%) 18 (6%) 0.70 34 (6%) 14 (5%) 0.52
Diarrhoea 165 (16%) 55 (10%) 0.003 80 (15%) 27 (10%) 0.034 135 (26%) 50 (18%) 0.007 85 (16%) 28 (10%) 0.033
Mucositis 11 (1%) 22 (4%) o0.001 5 (1%) 11 (4%) 0.008 16 (3%) 25 (9%) 0.001 6 (1%) 11 (4%) 0.016
Lethargy 212 (20%) 95 (18%) 0.18 94 (18%) 50 (19%) 0.90 120 (23%) 78 (28%) 0.16 118 (22%) 45 (16%) 0.042
PPE 41 (4%) 3 (1%) 0.001 25 (5%) 3 (1%) 0.016 65 (12%) 17 (6%) 0.007 16 (3%) 0 (0%) 0.002
Neuropathy 107 (10%) 72 (13%) 0.049 83 (16%) 59 (22%) 0.031 67 (13%) 36 (13%) 0.92 24 (5%) 13 (5%) 0.98
Thrombocytopenia 25 (2%) 12 (2%) 0.84 15 (3%) 7 (3%) 0.82 16 (3%) 7 (3%) 0.65 10 (2%) 5 (2%) 0.97
Neutropenia 32 (3%) 152 (28%) o0.001 15 (3%) 84 (32%) o0.001 10 (2%) 87 (31%) o0.001 17 (3%) 68 (25%) o0.001
Treatment-related infection 10 (1%) 52 (10%) o0.001 6 (1%) 22 (8%) o0.001 4 (1%) 24 (9%) o0.001 4 (1%) 30 (11%) o0.001
Treatment-related death 14 (1%) 8 (1%) 0.86 5 (1%) 5 (2%) 0.29 9 (2%) 1 (o1%) 0.13 9 (2%) 3 (1%) 0.53
Outcomes in first 12 weeks Arms A and C Arm A Arm B (þ cetuximab) Arm C
Oxaliplatin dose reduction 267 (25%) 128 (24%) 0.45 138 (26%) 71 (27%) 0.93 208 (40%) 89 (32%) 0.018 129 (24%) 57 (21%) 0.27
Fp dose reduction 429 (41%) 168 (31%) o0.001 220 (42%) 88 (33%) 0.009 315 (60%) 131 (47%) o0.001 209 (40%) 80 (29%) 0.004
Dose delay 466 (44%) 338 (62%) o0.001 236 (45%) 171 (64%) o0.001 261 (50%) 197 (71%) o0.001 230 (44%) 167 (60%) o0.001
Abbreviations: fp¼ fluoropyrimidine; OxCap¼ oxaliplatin/capecitabine; OxFU¼ oxaliplatin/leucovorin (LV)/infusional 5-FU; PPE¼ palmar-plantar erythema.
Table 4 G3þ toxicity: normal renal function vs mild renal impairment
Arms AþC (no cetuximab) Arm B (þ cetuximab)
OxCap OxFU OxCap OxFU
CrCl (mlmin 1) 480 50–80 480 50–80 480 50–80 480 50–80
G3þ toxicity N (%) N (%) P-value N (%) N (%) P-value N (%) N (%) P-value N (%) N (%) P-value
Any toxicity 275 (52%) 298 (60%) 0.047 162 (58%) 169 (67%) 0.060 197 (75%) 175 (72%) 0.16 120 (78%) 99 (82%) 0.72
Nausea 26 (5%) 53 (11%) 0.001 8 (3%) 17 (7%) 0.062 18 (7%) 24 (10%) 0.18 10 (6%) 6 (5%) 0.65
Vomiting 24 (5%) 32 (6%) 0.13 10 (4%) 10 (4%) 0.83 18 (7%) 16 (7%) 0.65 9 (6%) 8 (7%) 0.19
Diarrhoea 58 (11%) 95 (19%) 0.012 21 (7%) 28 (11%) 0.22 59 (22%) 69 (28%) 0.43 23 (15%) 23 (19%) 0.54
Mucositis 7 (1%) 3 (1%) 0.093 7 (2%) 11 (4%) 0.31 6 (2%) 8 (3%) 0.51 12 (8%) 11 (9%) 0.70
Lethargy 91 (17%) 106 (21%) 0.54 38 (14%) 45 (18%) 0.28 45 (17%) 71 (29%) 0.013 39 (25%) 37 (31%) 0.19
PPE 21 (4%) 18 (4%) 0.57 3 (1%) 0 (0%) NA 33 (13%) 29 (12%) 0.61 9 (6%) 7 (6%) 0.60
Neuropathy 52 (10%) 51 (10%) 0.85 31 (11%) 35 (14%) 0.94 36 (14%) 28 (11%) 0.36 20 (13%) 16 (13%) 0.40
Thrombocytopenia 6 (1%) 18 (4%) 0.009 6 (2%) 6 (2%) 0.94 9 (3%) 7 (3%) 0.73 1 (1%) 4 (3%) 0.47
Neutropenia 14 (3%) 14 (3%) 0.85 61 (22%) 76 (30%) 0.085 5 (2%) 5 (2%) 0.49 36 (23%) 44 (36%) 0.045
Treatment-related infection 4 (1%) 5 (1%) 0.25 28 (10%) 24 (9%) 0.83 2 (1%) 2 (1%) 0.84 10 (6%) 14 (12%) 0.13
Treatment-related death 4 (1%) 10 (2%) 0.098 5 (2%) 3 (1%) 0.52 4 (2%) 4 (2%) 0.83 1 (1%) 0 (0%) NA
Outcomes in first 12 weeks
Oxaliplatin dose reduction 108 (20%) 138 (28%) 0.33 63 (22%) 59 (23%) 0.86 93 (35%) 107 (44%) 0.49 40 (26%) 47 (39%) 0.043
Fp dose reduction 183 (35%) 226 (46%) 0.093 78 (28%) 83 (33%) 0.31 139 (53%) 163 (67%) 0.031 60 (39%) 68 (56%) 0.018
Dose delay 203 (38%) 241 (49%) 0.017 163 (58%) 169 (67%) 0.11 123 (47%) 128 (52%) 0.18 101 (66%) 92 (76%) 0.031
Abbreviations: CrCl¼ creatinine clearance; fp¼ fluoropyrimidine; OxCap¼ oxaliplatin/capecitabine; OxFU¼ oxaliplatin/leucovorin (LV)/infusional 5-FU; NA¼ not applicable;
PPE¼ palmar-plantar erythema.
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thus the risks and preferences for the individual patient should
inform the choice between OxCap and OxFU regimens. (IV)
Switching to a different oxaliplatin/Fp regimen is a valid option in
the event of controlled disease but poor tolerance or compliance
and should be considered before abandoning this regimen and
moving to a second-line regimen. (V) Patients with mild renal
impairment on OxCap or OxFUþ cetuximab should be monitored
closely for the development of severe toxicities and early and
appropriate dose reduction should be instituted if they occur.
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